{
    "clinical_study": {
        "@rank": "30368", 
        "brief_summary": {
            "textblock": "This study will assess an investigational medication for patients with severe primary\n      hyperparathyroidism or parathyroid cancer."
        }, 
        "brief_title": "A Study of an Investigational Medication for Severe Primary Hyperparathyroidism or Parathyroid Cancer", 
        "condition": [
            "Hyperparathyroidism", 
            "Parathyroid Neoplasms"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Neoplasms", 
                "Hyperparathyroidism", 
                "Parathyroid Neoplasms", 
                "Hyperparathyroidism, Primary"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "-  Patients must have parathyroid carcinoma or severe primary hyperparathyroidism; *\n             Abnormally elevated calcium levels above 12.5 mg/dL; * Not be pregnant or nursing; *\n             Not have had any type of cancer other than parathyroid carcinoma within the last 5\n             years."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": "46", 
        "firstreceived_date": "May 17, 2002", 
        "id_info": {
            "nct_id": "NCT00037518", 
            "org_study_id": "20000204"
        }, 
        "intervention": {
            "intervention_name": "AMG 073", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Calcimimetic Agents"
        }, 
        "keyword": [
            "Severe primary hyperparathyroidism", 
            "Parathyroid carcinoma"
        ], 
        "lastchanged_date": "May 6, 2013", 
        "link": {
            "description": "AmgenTrials clinical trials website", 
            "url": "http://www.amgentrials.com"
        }, 
        "number_of_arms": "1", 
        "official_title": "An Assessment of the Calcimimetic Agent AMG 073 for the Treatment of Subjects With Parathyroid Carcinoma or Intractable Primary Hyperparathyroidism.", 
        "overall_official": {
            "affiliation": "Amgen", 
            "last_name": "MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 4", 
        "primary_outcome": {
            "measure": "Changes in serum calcium and PTH"
        }, 
        "removed_countries": {
            "country": "United States"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00037518"
        }, 
        "responsible_party": {
            "name_title": "Global Development Leader", 
            "organization": "Amgen Inc."
        }, 
        "results_reference": [
            {
                "PMID": "17666472", 
                "citation": "Silverberg SJ, Rubin MR, Faiman C, Peacock M, Shoback DM, Smallridge RC, Schwanauer LE, Olson KA, Klassen P, Bilezikian JP. Cinacalcet hydrochloride reduces the serum calcium concentration in inoperable parathyroid carcinoma. J Clin Endocrinol Metab. 2007 Oct;92(10):3803-8. Epub 2007 Jul 31."
            }, 
            {
                "PMID": "19470620", 
                "citation": "Marcocci C, Chanson P, Shoback D, Bilezikian J, Fernandez-Cruz L, Orgiazzi J, Henzen C, Cheng S, Sterling LR, Lu J, Peacock M. Cinacalcet reduces serum calcium concentrations in patients with intractable primary hyperparathyroidism. J Clin Endocrinol Metab. 2009 Aug;94(8):2766-72. Epub 2009 May 26."
            }
        ], 
        "secondary_outcome": {
            "measure": "Safety and tolerability of cinacalcet"
        }, 
        "source": "Amgen", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Amgen", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2001", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2013"
    }, 
    "geocoordinates": {}
}